Imagen de Portada
Código QR

局限期小细胞肺癌治疗新格局： 从传统放化疗到精准治疗的新进展.

Limited-stage small cell lung cancer (LS-SCLC) is a highly aggressive malignancy with a poor prognosis. For a long time, the standard first-line treatment has been Etoposide plus Platinum-based chemotherapy combined with concurrent thoracic radiotherapy; however, most patients still face recurrence...

Descripción completa

Publicado en:Chinese Journal of Lung Cancer Vol. 29; no. 2; pp. 150 - 159
Autores principales: HAN, Jingwen, DAI, Keyao, MENG, Zixi, HUANG, Jun
Formato: research systematic review tables/charts Journal Article
Publicado: Chinese Journal of Lung Cancer Feb2026
Acceso en línea:Ver este registro en EBSCOhost
Sumario:Limited-stage small cell lung cancer (LS-SCLC) is a highly aggressive malignancy with a poor prognosis. For a long time, the standard first-line treatment has been Etoposide plus Platinum-based chemotherapy combined with concurrent thoracic radiotherapy; however, most patients still face recurrence and drug resistance. This article systematically reviews major recent advances in the field, aiming to illustrate the new paradigm shifting from conventional chemoradiotherapy toward precision-integrated therapy. Radiotherapy techniques continue to be optimized, and the value of surgery has been reaf- firmed in rigorously selected early-stage patients; immunotherapy has achieved a milestone breakthrough, with the ADRIATIC trial demonstrating that consolidation therapy with Durvalumab after chemoradiotherapy significantly extends median overall survival (55.9 vs 33.4 months); meanwhile, targeted therapies based on molecular subtyping also show promise. This paper clarifies the optimized directions of multimodal treatment strategies, emphasizes the guiding significance of molecular subtyping and biomarkers in individualized therapy, with the aim of providing reference for clinical practice, offering a framework for future research, and ultimately improving the survival outcomes of LS-SCLC patients as a whole.
局限期小细胞肺癌（limited-stage small cell lung cancer, LS-SCLC）是一种侵袭性强、预后差的恶性 肿瘤。长期以来，依托泊苷联合铂类化疗联合同步胸腔放疗是其标准一线治疗方案，但多数患者仍面临复发与耐 药。本文系统梳理近年来该领域的重大进展，旨在展现从传统放化疗向精准整合治疗转变的新格局。放疗技术持 续优化，手术在严格筛选的早期患者中价值被重新确立；免疫治疗实现里程碑突破，ADRIATIC研究证实放化疗后 Durvalumab巩固治疗可显著延长中位生存期（55.9 vs 33.4个月）；同时，基于分子分型的靶向治疗亦显示出潜力。 本文阐明多模式治疗策略的优化方向，强调分子分型与生物标志物在个体化治疗中的指导意义，以期为临床实践提 供参考，并为未来研究提供框架，从而整体提升LS-SCLC患者的生存预后。